drugset / Trial / NCT06439550
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab，Trastuzumab and SOX in the adjuvant treatment of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
Timeline
- Start
- 2024-07-15
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | S-1 | Small molecule | 40 mg/m2 | — |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |
Indications
No indication recorded.